Unlock stock picks and a broker-level newsfeed that powers Wall Street.
KSE - Delayed Quote KRW

Daewon Pharmaceutical Co., Ltd. (003220.KS)

Compare
13,400.00
+160.00
+(1.21%)
At close: April 4 at 3:30:26 PM GMT+9
Currency in KRW All numbers in thousands
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
598,162,352.61
598,162,352.61
526,952,045.06
478,884,656.36
354,176,435.16
Cost of Revenue
310,832,241.94
310,832,241.94
269,704,719.97
240,942,657.45
177,708,541.65
Gross Profit
287,330,110.67
287,330,110.67
257,247,325.09
237,941,998.91
176,467,893.51
Operating Expense
259,109,657
259,109,657
225,014,527
194,935,623
157,041,988
Operating Income
28,220,453.67
28,220,453.67
32,232,798.09
43,006,375.91
19,425,905.51
Net Non Operating Interest Income Expense
-7,679,432.53
-7,679,432.53
-3,334,976.89
-2,566,763.37
-1,807,561.57
Pretax Income
16,159,042.56
16,159,042.56
25,830,189.98
38,722,020.22
17,135,969.18
Tax Provision
6,055,242.26
6,055,242.26
2,366,928.60
8,064,848.63
10,525,293.27
Net Income Common Stockholders
14,209,540.70
14,209,540.70
23,916,930.91
31,944,350.70
6,988,825.61
Basic EPS
735.00
--
1.14k
1.51k
320.39
Diluted EPS
735.00
--
1.14k
1.48k
320.39
Basic Average Shares
19,332.71
--
20,979.76
21,155.20
21,813.61
Diluted Average Shares
19,332.71
--
20,979.76
21,613.23
21,813.61
Total Operating Income as Reported
28,220,453.53
28,220,453.53
32,232,798.51
43,006,376.51
19,425,905.25
Rent Expense Supplemental
1,005,877
1,005,877
713,204
807,120
830,283
Total Expenses
569,941,898.94
569,941,898.94
494,719,246.97
435,878,280.45
334,750,529.65
Net Income from Continuing & Discontinued Operation
14,209,540.70
14,209,540.70
23,916,930.91
31,944,350.70
6,988,825.61
Normalized Income
20,629,994.36
20,629,994.36
28,410,592.03
34,665,319.33
8,951,182.61
Interest Income
1,532,630
1,532,630
1,279,247
1,116,179
270,518
Interest Expense
9,305,859
9,305,859
4,614,224
3,682,942
2,078,079
Net Interest Income
-7,679,432.53
-7,679,432.53
-3,334,976.89
-2,566,763.37
-1,807,561.57
EBIT
25,464,901.56
25,464,901.56
30,444,413.98
42,404,962.22
19,214,048.18
EBITDA
45,559,435.56
45,559,435.56
48,005,127.98
61,772,963.22
37,019,414.18
Reconciled Cost of Revenue
310,832,241.94
310,832,241.94
269,704,719.97
240,942,657.45
177,708,541.65
Reconciled Depreciation
20,094,534
20,094,534
17,560,714
19,368,001
17,805,366
Net Income from Continuing Operation Net Minority Interest
15,268,611.53
15,268,611.53
23,916,930.91
31,944,350.70
6,988,825.61
Total Unusual Items Excluding Goodwill
-8,574,478
-8,574,478
-4,946,973
-3,436,762
-2,616,476
Total Unusual Items
-8,574,478
-8,574,478
-4,946,973
-3,436,762
-2,616,476
Normalized EBITDA
54,133,913.56
54,133,913.56
52,952,100.98
65,209,725.22
39,635,890.18
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-3,213,095.17
-3,213,095.17
-453,311.88
-715,793.37
-654,119
12/31/2021 - 9/29/2005

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade